Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor

被引:46
作者
Abouantoun, Thamara J.
MacDonald, Tobey J. [1 ]
机构
[1] George Washington Univ, Washington, DC 20010 USA
关键词
CHILDRENS CANCER GROUP; METASTATIC MEDULLOBLASTOMA; AKT INACTIVATION; KINASE INHIBITOR; PDGF RECEPTORS; OVARIAN-CANCER; EXPRESSION; TUMOR; PHOSPHORYLATION; GLEEVEC;
D O I
10.1158/1535-7163.MCT-08-0889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Platelet-derived growth factor (PDGF) receptor (PDGFR) expression correlates with metastatic medulloblastoma. PDGF stimulation of medulloblastoma cells phosphorylates extracellular signal-regulated kinase (ERK) and promotes migration. We sought to determine whether blocking PDGFR activity effectively inhibits signaling required for medulloblastoma cell migration and invasion. DAOY and D556 human medulloblastoma cells were treated with imatinib mesylate (Gleevec), a PDGFR tyrosine kinase inhibitor, or transfected with small interfering RNA (siRNA) to PDGFRB to test the effects of blocking PDGFR phosphorylation and expression, respectively. PDGFR cell signaling, migration, invasion, survival, and proliferation following PDGF-BB stimulation, with and without PDGFR inhibition, were measured. PDGF-BB treatment of cells increased PDGFRB, Akt and ERK phosphorylation, and transactivated epidermal growth factor receptor (EGFR), which correlated with enhanced migration, survival, and proliferation. Imatinib (1 mu mol/L) treatment of DAOY and D556 cells inhibited PDGF-BB- and serum-mediated migration and invasion at 24 and 48 h, respectively, and concomitantly inhibited PDGF-BB activation of PDGFRB, Akt, and ERK but increased PTEN expression and activity. Imatinib treatment also induced DAOY cell apoptosis at 72 h and inhibited DAOY and D556 cell proliferation at 48 h. siRNA silencing of PDGFRB similarly inhibited signaling, migration, and survival and both siRNA and imatinib treatment inhibited PDGF-BB-mediated EGFR transactivation, indicating that the effects of imatinib treatment are specific to PDGFRB target inhibition. These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma. [Mol Cancer Ther 2009;8(5):1137-47]
引用
收藏
页码:1137 / 1147
页数:11
相关论文
共 50 条
  • [21] Platelet-derived growth factor receptor α gene is regulated by multiple first exons
    Minato, Yusuke
    Kuwahara-Otani, Sachi
    Maeda, Seishi
    Yagi, Hideshi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 510 (04) : 489 - 494
  • [22] Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC
    Kilvaer, Thomas Karsten
    Rakaee, Mehrdad
    Hellevik, Turid
    Vik, Jorg
    De Petris, Luigi
    Donnem, Tom
    Strell, Carina
    Ostman, Arne
    Busund, Lill-Tove Rasmussen
    Martinez-Zubiaurre, Inigo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
    Roh, Ju-Won
    Huang, Jie
    Hu, Wei
    Yang, XiaoYun
    Jennings, Nicholas B.
    Sehgal, Vasudha
    HwaSohn, Bo
    Han, Hee Dong
    Lee, Sun Joo
    Thanapprapasr, Duangmani
    Bottsford-Miller, Justin
    Zand, Behrouz
    Dalton, Heather J.
    Previs, Rebecca A.
    Davis, Ashley N.
    Matsuo, Koji
    Lee, Ju-Seog
    Ram, Prahlad
    Coleman, Robert L.
    Sood, Anil K.
    CLINICAL CANCER RESEARCH, 2014, 20 (10) : 2740 - 2750
  • [24] PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR ACTIVATION IN CELL-TRANSFORMATION AND HUMAN MALIGNANCY
    FLEMING, TP
    MATSUI, T
    AARONSON, SA
    EXPERIMENTAL GERONTOLOGY, 1992, 27 (5-6) : 523 - 532
  • [25] Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
    Yu, Yi
    Zhang, Mingxing
    Zhang, Xiaoyan
    Cai, Qingqing
    Hong, Shanshan
    Jiang, Wei
    Xu, Congjian
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [26] Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells
    Yoon, JH
    Gwak, GY
    Lee, HS
    Bronk, SF
    Werneburg, NW
    Gores, GJ
    JOURNAL OF HEPATOLOGY, 2004, 41 (05) : 808 - 814
  • [27] Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma
    Yonemori, Kan
    Tsuta, Koji
    Ando, Masashi
    Hirakawa, Akihiro
    Hatanaka, Yutaka
    Matsuno, Yoshihiro
    Chuman, Hirokazu
    Yamazaki, Naoya
    Fujiwara, Yasuhiro
    Hasegawa, Tadashi
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) : 2841 - 2850
  • [28] TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation
    Rayego-Mateos, Sandra
    Luis Morgado-Pascual, Jose
    Belen Sanz, Ana
    Mario Ramos, Adrian
    Eguchi, Satoru
    Batlle, Daniel
    Pato, Janos
    Keri, Gyorgy
    Egido, Jesus
    Ortiz, Alberto
    Ruiz-Ortega, Marta
    JOURNAL OF PATHOLOGY, 2013, 231 (04) : 480 - 494
  • [29] Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma
    Matsuo, Koji
    Nishimura, Masato
    Komurov, Kakajan
    Shahzad, Mian M. K.
    Ali-Fehmi, Rouba
    Roh, Ju-Won
    Lu, Chunhua
    Cody, Dianna D.
    Ram, Prahlad T.
    Loizos, Nick
    Coleman, Robert L.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (01) : 166 - 175
  • [30] Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas
    Chang, Kevin K.
    Yoon, Changhwan
    Yi, Brendan C.
    Tap, William D.
    Simon, M. Celeste
    Yoon, Sam S.
    ONCOGENESIS, 2018, 7